感染疾病疫苗合作與授權協議（2016-2026 年）

感染疾病疫苗交易的權威基準

感染疾病疫苗合作的形成受到全球衛生優先事項、感染疾病疫情需求以及公共和私人相關人員之間合作的影響，其合約結構既體現了策略準備，也體現了商業性考慮。

本報告對超過 590 項感染疾病疫苗合作與許可協議進行了全面系統的分析，清晰且有實證支持地闡述了整個市場夥伴關係的設計、談判和執行方式。

充分了解市場標準。

本報告將幫助您準確了解感染疾病疫苗交易的實際結構，使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解合約條款如何因技術平台、適應症和合作夥伴情況而異。
• 支持實證評估和結構性決策
• 內部討論應基於實際交易數據，而非假設。
• 了解大型公司如何處理交易
• 這可視化了受政策影響的全球調整環境下的合作夥伴行為和重複交易結構。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，使您能夠詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解感染疾病疫苗夥伴關係中價值、風險和控制權的分配至關重要，尤其是在需要快速反應、大規模生產和公共部門參與的情況下。
• 專為實際業務拓展和策略制定而設計。

本報告主要廣泛用於以下用途：

• 建構和基準化實際交易
• 在清晰的市場環境下準備談判
• 合作機會及目的地評估
• 支援穩健且引人注目的數據驅動型內部策略
• 內容
• 超過 590 項與感染疾病疫苗相關的合作和許可協議。
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 可全文搜尋的合約目錄（依公司、技術和適應症分類）。
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 交易趨勢分析、關鍵交易案例分析和活躍交易相關人員分析。
• 關於感染疾病疫苗交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易報告和合約層面的深入分析，為如何建立、談判和評估與感染疾病疫苗相關的夥伴關係提供了可靠的、基於證據的參考資料。

目錄

執行摘要

第1章：引言

第2章：感染疾病交易趨勢

• 介紹
• 感染疾病疫苗長期貿易
• 最活躍的感染疾病相關人員
• 感染疾病疫苗交易（依交易類型）
• 感染疾病疫苗交易（依治療區域分類）
• 感染疾病疫苗交易（按行業分類）
• 感染疾病疫苗的貿易條款

第3章：主要感染疾病疫苗交易

• 介紹
• 按價值排名的前幾大感染疾病疫苗交易

第4章：感染疾病疫苗交易相關人員

• 介紹
• 最活躍的感染疾病相關人員
• 最活躍的感染疾病疫苗交易公司簡介

第5章：感染疾病疫苗合約交易目錄

• 介紹
• 感染疾病合約交易目錄

第6章：感染疾病疫苗按技術類型分類的貿易

• 交易清單
• 交易清單 -感染疾病疫苗交易資訊（AZ）（按公司）
• 交易清單 -感染疾病疫苗交易（依交易類型）
• 交易清單 -感染疾病疫苗交易（依治療區域分類）
• 交易類型的定義
• 關於這家研究公司
• 當前夥伴關係
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for infectious vaccine dealmaking

Infectious vaccine partnering is shaped by global health priorities, outbreak-driven demand, and collaboration between public and private sector stakeholders, with deal structures reflecting both strategic preparedness and commercial considerations.

This report provides a comprehensive and structured analysis of 590+ infectious vaccine collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how infectious vaccine deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by technology platform, indication, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a policy-influenced and globally coordinated landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within infectious vaccine partnerships, particularly in settings involving rapid response, large-scale manufacturing, and public sector engagement.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 590+ infectious vaccine collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, technology, and indication)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for infectious vaccine dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how infectious vaccine partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious vaccine dealmaking

• 2.1. Introduction
• 2.2. Infectious vaccine deals over the years
• 2.3. Most active infectious vaccine dealmakers
• 2.4. Infectious vaccine deals by deal type
• 2.5. Infectious vaccine deals by therapy area
• 2.6. Infectious vaccine deals by industry sector
• 2.7. Deal terms for infectious vaccine deals
  • 2.7.1 Infectious vaccine deals headline values
  • 2.7.2 Infectious vaccine deal upfront payments
  • 2.7.3 Infectious vaccine deal milestone payments
  • 2.7.4 Infectious vaccine royalty rates

Chapter 3 - Leading infectious vaccine deals

• 3.1. Introduction
• 3.2. Top infectious vaccine deals by value

Chapter 4 - Most active infectious vaccine dealmakers

• 4.1. Introduction
• 4.2. Most active infectious vaccine dealmakers
• 4.3. Most active infectious vaccine deals company profiles

Chapter 5 - Infectious vaccine contracts dealmaking directory

• 5.1. Introduction
• 5.2. Infectious vaccine contracts dealmaking directory

Chapter 6 - Infectious vaccine dealmaking by technology type

• Deal directory
• Deal directory - Infectious vaccine deals by company A-Z
• Deal directory - Infectious vaccine deals by deal type
• Deal directory - Infectious vaccine deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Infectious vaccine deals since 2016
• Figure 2: Active infectious vaccine dealmaking activity since 2016
• Figure 3: Infectious vaccine deals by deal type since 2016
• Figure 4: Infectious vaccine deals by therapy area since 2016
• Figure 5: Infectious vaccine deals by industry sector since 2016
• Figure 6: Infectious vaccine deals with a headline value
• Figure 7: Infectious vaccine deals with an upfront value
• Figure 8: Infectious vaccine deals with a milestone value
• Figure 9: Infectious vaccine deals with a royalty rate value
• Figure 10: Top infectious vaccine deals by value since 2016
• Figure 11: Most active infectious vaccine dealmakers since 2016
• Figure 12: Infectious vaccine deals by technology type since 2016